Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer.

ABSTRACT:

Background

Approximately 35% of patients with non-small cell lung cancer (NSCLC) have locally advanced disease. Despite treatment with chemoradiotherapy (CRT) and consolidation immunotherapy, overall survival remains below 50% at 5 years. Kirsten rat sarcoma (KRAS) mutations (KRASms) are the most common lung cancer mutations, affecting 25% of NSCLC cases. KRASm can cause radioresistance, and several targeted KRASm therapies have been developed, mainly targeting the KRAS G12C mutation (KRASm G12C), but the impact of KRASm G12C on the efficacy of CRT for locally advanced NSCLC remains unclear.

Methods

We conducted a multicenter retrospective study of unresectable stage II or III NSCLC treated with CRT in four French hospitals be

SUBMITTER: Cabon J 

PROVIDER: S-EPMC12695551 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature